Q-omics provides the consensus-scored C16orf71 profile across patient tissues and cancer cell-line models. C16orf71 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, C16orf71 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, C16orf71 RNA expression shows 17,607 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, THCA, and TGCT as cancer lineages where C16orf71 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C16orf71 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C16orf71 survival associations across molecular data types. C16orf71 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C16orf71 RNA expression–survival associations across cancer types. High C16orf71 expression shows unfavorable associations in LGG and BLCA, but favorable associations in BRCA, HNSC, DLBC and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify BRCA as the clearest survival context for C16orf71 RNA expression.
This table summarizes C16orf71 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C16orf71. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C16orf71 shows lower tumor expression in THCA, KICH and LUSC and higher tumor expression in LIHC, BRCA and KIRP. The THCA box plot shows higher C16orf71 RNA expression in normal versus tumor tissue (log2 FC = −1.158, t-test p < 0.001).
This table shows molecular features associated with C16orf71 in patient tissues and cancer cell lines. In patient samples, C16orf71 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C16orf71 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
